Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

Peptide vaccines for hepatocellular carcinoma

(2013) Daisuke Nobuoka et al.   Human Vaccines & Immunotherapeutics

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

(2012) Tim F Greten et al.   BMC CANCER

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

(2012) Yu Sawada et al.   OncoImmunology

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells

(2011) Toshiaki Yoshikawa et al.   CANCER SCIENCE

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

(2009) Hirofumi Shirakawa et al.   CANCER SCIENCE

Spontaneous regression of hepatocellular carcinoma: a systematic review

(2009) Susana Oquiñena et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY